Clinical Trials

72 results for Prostate Cancer


Randomized Phase II Trial of Five or Two MRI-Guided Adaptive Radiotherapy Treatments for Prostate Cancer

  • Condition: Prostate Cancer
  • Study ID: NCT04984343
View Trial

Randomized Phase II Trial of Salvage Radiotherapy for Prostate Cancer In 4 Weeks v. 2 Weeks

  • Condition: Prostate Cancer
  • Study ID: NCT04422132
View Trial

Feasibility Study of Radiation Therapy and IRreversible Electroporation for Intermediate Risk Prostate Cancer (RTIRE)

  • Condition: Prostate Cancer
  • Study ID: NCT05345444
View Trial

Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)

  • Condition: Prostate Adenocarcinoma
  • Study ID: NCT05050084
View Trial

A Phase 2 Trial of ADT Interruption in Patients Responding Exceptionally to AR-Pathway Inhibitor in Metastatic Hormone-Sensitive Prostate Cancer (MHSPC): A-DREAM

  • Condition: Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
  • Study ID: NCT05241860
View Trial

A Phase I/IIa Theranostic Study of 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer

  • Condition: Prostatic Neoplasms, Castration-Resistant
  • Study ID: NCT04868604
View Trial

A Phase 1/2 Study of EPI-7386 in Combination With Enzalutamide Compared With Enzalutamide Alone in Subjects With Metastatic Castration-Resistant Prostate Cancer

  • Condition: Prostate Cancer
  • Study ID: NCT05075577
View Trial

A Phase 1, Open-label Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral EPI-7386 in Patients With Metastatic Castration-Resistant Prostate Cancer

  • Condition: Prostate Cancer
  • Study ID: NCT04421222
View Trial

AcTION: A Phase I Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer and Extensive Skeletal Metastases

  • Condition: Prostatic Neoplasms, Castration-Resistant
  • Study ID: NCT04597411
View Trial

SatisfACtion: A Phase I/II, Open-label, Multi-center Study of [225Ac]Ac-PSMA-R2 in Men With Heavily Pre-treated PSMA Positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without Prior 177Lu-labelled PSMA-targeted Radioligand Therapy.

  • Condition: Metastatic Castration-resistant Prostate Cancer (mCRPC)
  • Study ID: NCT05983198
View Trial

A Phase IV, Post-Authorization Safety Study to Investigate the Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Adult Participants With Prostate Cancer

  • Condition: Prostate Cancer
  • Study ID: NCT05803941
View Trial

A Prospective, Open-label, Multi-center, Single-arm, Phase II Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive Metastatic Castration-Resistant Prosta

  • Condition: Metastatic Castration-Resistant Prostate Cancer (mCRPC)
  • Study ID: NCT05670106
View Trial

An Open-label, Multi-center, Randomized, Phase II Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in the Treatment of Taxane Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer

  • Condition: Metastatic Castration-Resistant Prostate Cancer (mCRPC)
  • Study ID: NCT05658003
View Trial

A Phase 4, Randomized, Open-label, Multicenter Efficacy and Safety Study of Standard Dose of Radium-223 Dichloride vs. Standard Doses of Novel Anti-hormonal Therapy (NAH) in Patients With Bone Dominant Metastatic Castration Resistant Prostate Cancer (mCRP

  • Condition: Metastatic Castrate Resistant Prostate Cancer (mCRPC)
  • Study ID: NCT04597125
View Trial

A Phase 1 Open-label, First-in-human, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Actinium-225-macropa-pelgifatamab (BAY 3546828) in Participants With Advanced Metastatic Castration Resistant Prostat

  • Condition: Metastatic Castration-resistant Prostate Cancer
  • Study ID: NCT06052306
View Trial

Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR): A Randomized Multi-center Study for Men With Newly Diagnosed Favorable Risk Prostate Cancer

  • Condition: Prostate Cancer
  • Study ID: NCT04396808
View Trial

Phase I/II Trial of Pembrolizumab and Androgen-receptor Pathway Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer

  • Condition: Prostate Cancer
  • Study ID: NCT04946370
View Trial

Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer

  • Condition: Metastatic Castration-resistant Prostate Cancer, mCRPC
  • Study ID: NCT05340374
View Trial

Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men With Metastatic Castration-Resistant Prostate Cancer

  • Condition: Metastatic Castration-resistant Prostate Cancer, mCRPC, Prostate Cancer
  • Study ID: NCT05383079
View Trial

A Phase I/II Study of Bintrafusp Alfa (M7824) and M9241 in Combination With Docetaxel in Adults With Metastatic Castration Sensitive and Castration Resistant Prostate Cancer

  • Condition: Cancer Of Prostate, Prostate Neoplasms
  • Study ID: NCT04633252
View Trial

A Phase 2 Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With BRCA1/2 Gene Alterations (NePtune)

  • Condition: Prostate Cancer, BRCA1 Mutation, BRCA2 Mutation, Prostatic Adenocarcinoma, High-Risk Cancer
  • Study ID: NCT05498272
View Trial

Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy: A Prospective, Single-arm, Multi-center, Blinded-review, Phase 3 Diagnostic Performance Study

  • Condition: Prostate Cancer, Prostatic Neoplasms
  • Study ID: NCT06056830
View Trial